Navigation Links
DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
Date:3/27/2013

Los Angeles, CA (PRWEB) March 27, 2013

The drug safety advocates at DrugRisks.com are announcing updated legal news on the site for patients who have taken the diabetes drug Actos. The first trial began this month for a retired man who alleges he developed bladder cancer after taking the medication.

DrugRisks was created to provide those taking popular prescription drugs like Actos with the latest safety alerts, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

Health experts with the FDA and European Medicines Agency* have warned that use of Actos for extended amounts of time may be linked to an increased risk of bladder cancer. Regulators in France and Germany have also banned its use**.

In the United States, as many as 3,000 patients have filed an Actos lawsuit against drug maker Takeda Pharmaceuticals over allegations of bladder cancer***. Over 1,200 of these have been consolidated in a special multi-district federal court in Louisiana, while others are pending in California.

Now, DrugRisks has learned that the first Actos lawsuit trial began this month in California for a retired man who alleges the drug has left him terminally ill from bladder cancer***. At the trial, a former pharmacologist for Takeda testified that the company was more concerned with continued sales of the drug rather than the safety of patients***.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).

Read the full story at http://www.prweb.com/releases/actos-bladder-cancer/actos-lawsuit/prweb10573586.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Frozen Food Production in the US Industry Market Research Report from IBISWorld has Been Updated
2. Fitment Guide Update for the 2012 Land Rover Range Rover Evoque, Made by SizeItUp
3. Hip Safety Center Update: Patients Ask to Send Stryker Hip Lawsuits to Federal Court
4. Drug Safety Center Update: Employee Alleges Actos Maker Valued Sales Over Safety
5. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
6. Update: Number of Stryker Rejuvenate Hip Recall Lawsuits Growing in New Jersey Multicounty Litigation, Announces Wright & Schulte LLC
7. Harmonic Software Systems Announces an Updated Version of Their DigitalMeds iPhone App
8. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
9. Updated stereo EEG workflow simplifies planning of epilepsy surgery
10. American Emu Association Updates Quality Regulations in Response to Fraudulent Oils in Market
11. Tylenol Liver Failure Allegation Lawsuits Update: Resource4thePeople Reports Hearing to Consolidate Federal Cases Is Scheduled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... will lecture to primary eye care practitioners on the latest breakthroughs in the ... 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New ... the region, is launching a charity drive to raise awareness of heart disease and ... killer in America, and is responsible for 1 in every 4 deaths at the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... Tyler, TX (PRWEB) , ... January 17, 2017 ... ... serving Texas families from two offices in Tyler, has announced the latest beneficiary ... Red Ribbon Wish Network, a nonprofit organization dedicated to fulfilling the dreams of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene ... vice president, research and pharmaceutical development at Tocagen, will present at ... held Jan. 17-20 in Miami . ... ... manufacturing for replicating viruses - what to do when and why ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, ... Forecast to 2021" report to their offering. ... The global active pharmaceutical ingredients ... USD 157.95 Billion in 2016, growing at a CAGR of 6.3% ...
(Date:1/17/2017)... , Jan. 17, 2017 Immune Pharmaceuticals (NASDAQ: ... company, announced today that it will hold a Satellite Symposium ... Acute Leukemias (ISAL) XVI in Munich, Germany ... "Reinforcing the Efficacy of Immunotherapy for the maintenance of ... on Monday February 20 th , 2017 from 12:45 – ...
Breaking Medicine Technology: